These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 14584071

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Estrogen and progesterone receptor expression in postmenopausal tamoxifen-exposed endometrial pathologies.
    Cohen I, Beyth Y, Altaras MM, Shapira J, Tepper R, Cardoba M, Yigael D, Figer A, Fishman A, Berenhein J.
    Gynecol Oncol; 1997 Oct; 67(1):8-15. PubMed ID: 9345349
    [Abstract] [Full Text] [Related]

  • 4. Alterations of the K-ras and p53 genes in Tamoxifen-associated endometrial carcinoma.
    Fujiwara K, Enomoto T, Fujita M, Kanda T, Fujii S, Ito K, Wakasa K, Ishiko O, Ueda M, Yamaguchi S, Kimura T, Umesaki N.
    Oncol Rep; 2008 May; 19(5):1293-8. PubMed ID: 18425390
    [Abstract] [Full Text] [Related]

  • 5. Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer.
    Dibi RP, Zettler CG, Pessini SA, Ayub AV, de Almeida SB, da Silveira GP.
    Menopause; 2009 May; 16(2):293-300. PubMed ID: 19034048
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Apoptosis as a possible candidate mechanism for removal of tamoxifen-related endometrial cells with KRAS mutations.
    Tsujioka H, Hachisuga T, Hikita S, Ueda T, Yotsumoto F, Shirota K, Yoshizato T, Kawarabayashi T, Kuroki M, Miyamoto S.
    Anticancer Res; 2010 Aug; 30(8):3119-23. PubMed ID: 20871029
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Tamoxifen and giant endometrial polyps].
    Caschetto S, Cassaro N, Consalvo P, Caragliano L.
    Minerva Ginecol; 2000 Nov; 52(11):459-63. PubMed ID: 11256174
    [Abstract] [Full Text] [Related]

  • 10. Molecular markers in the endometrium at baseline of postmenopausal patients with early breast cancer in the ATAC (Arimidex, tamoxifen, alone, or in combination) trial.
    Duffy SR, Taylor L.
    Am J Obstet Gynecol; 2004 Dec; 191(6):1921-7. PubMed ID: 15592273
    [Abstract] [Full Text] [Related]

  • 11. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study.
    Wilder JL, Shajahan S, Khattar NH, Wilder DM, Yin J, Rushing RS, Beaven R, Kaetzel C, Ueland FR, van Nagell JR, Kryscio RJ, Lele SM.
    Gynecol Oncol; 2004 Feb; 92(2):553-8. PubMed ID: 14766247
    [Abstract] [Full Text] [Related]

  • 12. Estrogen and progesterone receptors in the endometrium of postmenopausal breast cancer patients treated with tamoxifen and progestogens.
    Cohen I, Altaras MM, Beyth Y, Shapira J, Figer A, Tepper R, Cordoba M, Yigal D, Bernheim J.
    Gynecol Oncol; 1997 Apr; 65(1):83-8. PubMed ID: 9103396
    [Abstract] [Full Text] [Related]

  • 13. Expression of the inhibin/activin subunits alpha (alpha), beta-A (betaA) and beta-B (betaB) in benign human endometrial polyps and tamoxifen-associated polyps.
    Mylonas I, Makovitzky J, Fernow A, Richter DU, Jeschke U, Briese V, Gerber B, Friese K.
    Arch Gynecol Obstet; 2005 Jun; 272(1):59-66. PubMed ID: 15309402
    [Abstract] [Full Text] [Related]

  • 14. [Dualistic model of molecular pathogenesis in endometrial carcinoma].
    Lax SF.
    Zentralbl Gynakol; 2002 Jan; 124(1):10-6. PubMed ID: 11873308
    [Abstract] [Full Text] [Related]

  • 15. Does tamoxifen therapy affect the hormone receptor expression and cell proliferation indices of endometrial polyps? An immunohistochemical comparison of endometrial polyps from postmenopausal women exposed and not exposed to tamoxifen.
    McGurgan P, Taylor LJ, Duffy SR, O'Donovan PJ.
    Maturitas; 2006 Jun 20; 54(3):252-9. PubMed ID: 16413707
    [Abstract] [Full Text] [Related]

  • 16. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
    Lax SF, Kurman RJ.
    Verh Dtsch Ges Pathol; 1997 Jun 20; 81():228-32. PubMed ID: 9474874
    [Abstract] [Full Text] [Related]

  • 17. Expression of estrogen receptors alpha and beta, and progesterone receptors A and B in human mucinous carcinoma of the endometrium.
    Shabani N, Mylonas I, Jeschke U, Thaqi A, Kuhn C, Puchner T, Friese K.
    Anticancer Res; 2007 Jun 20; 27(4A):2027-33. PubMed ID: 17649817
    [Abstract] [Full Text] [Related]

  • 18. Monitoring of endometrial K-ras mutation in tamoxifen-treated patients with breast cancer.
    Tsujioka H, Hachisuga T, Fukuoka M, Ueda T, Miyahara D, Horiuchi S, Shirota K, Yoshizato T, Emoto M, Miyamoto S, Kawarabayashi T.
    Int J Gynecol Cancer; 2009 Aug 20; 19(6):1052-6. PubMed ID: 19820367
    [Abstract] [Full Text] [Related]

  • 19. Malignant endometrial polyps in postmenopausal breast cancer tamoxifen-treated patients.
    Cohen I, Bernheim J, Azaria R, Tepper R, Sharony R, Beyth Y.
    Gynecol Oncol; 1999 Oct 20; 75(1):136-41. PubMed ID: 10502440
    [Abstract] [Full Text] [Related]

  • 20. Metastatic breast lobular carcinoma involving tamoxifen-associated endometrial polyps: report of two cases and review of tamoxifen-associated polypoid uterine lesions.
    Houghton JP, Ioffe OB, Silverberg SG, McGrady B, McCluggage WG.
    Mod Pathol; 2003 Apr 20; 16(4):395-8. PubMed ID: 12692205
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.